Javier Cortes

List of Publications by Year in descending order

258 papers	26,550 citations	18465 62 h-index	6831 155 g-index
263 all docs	263 docs citations	263 times ranked	21937 citing authors

#	Article	IF	Citations
1	Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer. New England Journal of Medicine, 2012, 366, 109-119.	13.9	2,155
2	Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer. New England Journal of Medicine, 2015, 372, 724-734.	13.9	1,658
3	Pembrolizumab for Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2020, 382, 810-821.	13.9	1,542
4	Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine, 2020, 382, 610-621.	13.9	1,143
5	Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet, The, 2020, 396, 1817-1828.	6.3	992
6	Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet, The, 2011, 377, 914-923.	6.3	949
7	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA) Tj ETQq1 1 0.784314 rgBT /Overlock Lancet Oncology, The, 2013, 14, 461-471.	5.1	849
8	Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 3239-3247.	0.8	812
9	Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer. Journal of the National Cancer Institute, 2007, 99, 628-638.	3.0	769
10	Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nature Communications, 2015, 6, 8839.	5.8	605
11	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
12	Phase II Trial of Pertuzumab and Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2â€“Positive Metastatic Breast Cancer That Progressed During Prior Trastuzumab Therapy. Journal of Clinical Oncology, 2010, 28, 1138-1144.	0.8	593
13	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptorâ€“Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.4	509
14	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012, 2, 1036-1047.	7.7	507
15	MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2â^' Metastatic Breast Cancer. Clinical Cancer Research, 2017, 23, 5218-5224.	3.2	492
16	Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2â^', Node-Positive, High-Risk, Early Breast Cancer (monarchE). Journal of Clinical Oncology, 2020, 38, 3987-3998.	0.8	478
17	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. New England Journal of Medicine, 2022, 386, 1143-1154.	13.9	474
18	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine, 2022, 386, 556-567.	13.9	444

#	Article	IF	Citations
19	Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology, The, 2017, 18, 904-916.	5.1	427
20	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	13.5	376
21	Phase III Open-Label Randomized Study of Eribulin Mesylate Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane. Journal of Clinical Oncology, 2015, 33, 594-601.	0.8	365
22	HER2-Low Breast Cancer: Pathological and Clinical Landscape. Journal of Clinical Oncology, 2020, 38, 1951-1962.	0.8	353
23	Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in Human Epidermal Growth Factor Receptor 2â€“Positive, First-Line Metastatic Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3753-3761.	0.8	296
24	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	3.3	291
25	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	5.8	276
26	Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2021, 22, 499-511.	5.1	260
27	HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncology, The, 2017, 18, 545-554.	5.1	250
28	First-Line Treatment of Advanced Breast Cancer With Sunitinib in Combination With Docetaxel Versus Docetaxel Alone: Results of a Prospective, Randomized Phase III Study. Journal of Clinical Oncology, 2012, 30, 921-929.	0.8	244
29	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 2020, 38, 423-433.	0.8	240
30	Pertuzumab Monotherapy After Trastuzumab-Based Treatment and Subsequent Reintroduction of Trastuzumab: Activity and Tolerability in Patients With Advanced Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2012, 30, 1594-1600.	0.8	221
31	Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2010, 28, 1131-1137.	0.8	214
32	Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine. Journal of Clinical Oncology, 2010, 28, 3922-3928.	0.8	194
33	Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial. Journal of Clinical Oncology, 2022, 40, 3246-3256.	0.8	190
34	Molecular Features and Survival Outcomes of the Intrinsic Subtypes Within HER2-Positive Breast Cancer. Journal of the National Cancer Institute, 2014, 106, .	3.0	178
35	Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies. Breast Cancer Research and Treatment, 2014, 148, 553-561.	1.1	174
36	Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: Evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. European Journal of Cancer, 2018, 89, 27-35.	1.3	172

#	Article	IF	Citations
37	Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nature Reviews Clinical Oncology, 2013, 10, 377-389.	12.5	164
38	Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocrine-Related Cancer, 2007, 14, 221-232.	1.6	142
39	Cardiac Tolerability of Pertuzumab Plus Trastuzumab Plus Docetaxel in Patients With HER2â€Positive Metastatic Breast Cancer in CLEOPATRA: A Randomized, Doubleâ€Blind, Placeboâ€Controlled Phase III Study. Oncologist, 2013, 18, 257-264.	1.9	137
40	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.. Journal of Clinical Oncology, 2020, 38, 1000-1000.	0.8	135
41	MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients. Oncotarget, 2015, 6, 37269-37280.	0.8	135
42	Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones. Oncologist, 2007, 12, 271-280.	1.9	132
43	Antibodyâ€“drug conjugates: Smart chemotherapy delivery across tumor histologies. Ca-A Cancer Journal for Clinicians, 2022, 72, 165-182.	157.7	132
44	Front-Line Paclitaxel/Cisplatin-Based Chemotherapy in Brain Metastases from Non-Small-Cell Lung Cancer. Oncology, 2003, 64, 28-35.	0.9	126
45	Enhancing global access to cancer medicines. Ca-A Cancer Journal for Clinicians, 2020, 70, 105-124.	157.7	123
46	Safety and Efficacy of Neratinib in Combination With Capecitabine in Patients With Metastatic Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2014, 32, 3626-3633.	0.8	118
47	Phase III study of taselisib (GDC-0032) + fulvestrant (FULV) v FULV in patients (pts) with estrogen receptor (ER)-positive, PIK3CA-mutant (MUT), locally advanced or metastatic breast cancer (MBC): Primary analysis from SANDPIPER.. Journal of Clinical Oncology, 2018, 36, LBA1006-LBA1006.	0.8	116
48	Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial. Lancet Oncology, The, 2015, 16, 1700-1710.	5.1	108
49	Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts. Clinical Cancer Research, 2017, 23, 649-657.	3.2	108
50	Phase III Trials of Eribulin Mesylate (E7389) in Extensively Pretreated Patients With Locally Recurrent or Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 160-163.	1.1	101
51	Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2015, 33, 1003-1003.	0.8	101
52	Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncology, The, 2018, 19, 812-824.	5.1	98
53	HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade. Journal of the National Cancer Institute, 2020, 112, 46-54.	3.0	97
54	The Genomic and Immune Landscapes of Lethal Metastatic Breast Cancer. Cell Reports, 2019, 27, 2690-2708.e10.	2.9	95

#	Article	IF	Citations
55	Next Generation-Targeted Amplicon Sequencing (NG-TAS): an optimised protocol and computational pipeline for cost-effective profiling of circulating tumour DNA. Genome Medicine, 2019, 11, 1.	3.6	84
56	Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel. Clinical Cancer Research, 2018, 24, 5820-5829.	3.2	82
57	Etirinotecan pegol (NKTR-102) versus treatment of physician's choice in women with advanced breast cancer previously treated with an anthracycline, a taxane, and capecitabine (BEACON): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncology, The, 2015, 16, 1556-1568.	5.1	79
58	Association of Pathologic Complete Response with Long-Term Survival Outcomes in Triple-Negative Breast Cancer: A Meta-Analysis. Cancer Research, 2020, 80, 5427-5434.	0.4	77
59	High HER2 protein levels correlate with increased survival in breast cancer patients treated with antiâ€HER2 therapy. Molecular Oncology, 2016, 10, 138-147.	2.1	76
60	Hepatic Resection for Liver Metastases as Part of the â€œOncosurgicalâ€•Treatment of Metastatic Breast Cancer. Annals of Surgical Oncology, 2008, 15, 2804-2810.	0.7	75
61	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	3.2	71
62	Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial. Clinical Cancer Research, 2020, 26, 5820-5829.	3.2	68
63	Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (Pts) with hormone receptorâ€“positive/HER2-negative (HR+/HER2-) advanced breast cancer.. Journal of Clinical Oncology, 2022, 40, LBA1001-LBA1001.	0.8	68
64	Prognostic factors for disease-free survival in patients with T3â€“4 or N+ rectal cancer treated with preoperative chemoradiation therapy, surgery, and intraoperative irradiation. International Journal of Radiation Oncology Biology Physics, 2006, 64, 1122-1128.	0.4	67
65	Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade. Nature Communications, 2020, 11, 385.	5.8	67
66	Immunotherapy for early triple negative breast cancer: research agenda for the next decade. Npj Breast Cancer, 2022, 8, 23.	2.3	67
67	Nonpegylated Liposomal Doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-Overexpressing Breast Cancer: A Multicenter Phase I/II Study. Clinical Cancer Research, 2009, 15, 307-314.	3.2	65
68	Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptorâ€“Positive Metastatic Breast Cancer. JAMA Oncology, 2019, 5, 1556.	3.4	62
69	Tumor-Infiltrating Lymphocytes in Patients Receiving Trastuzumab/Pertuzumab-Based Chemotherapy: A TRYPHAENA Substudy. Journal of the National Cancer Institute, 2019, 111, 69-77.	3.0	60
70	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncology, The, 2021, 22, 858-871.	5.1	60
71	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. Biochimica Et Biophysica Acta: Reviews on Cancer, 2017, 1868, 527-537.	3.3	59
72	p95HER2â€“T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	5.8	59

#	Article	IF	Citations
73	IMpassion132 Phase III trial: atezolizumab and chemotherapy in early relapsing metastatic triple-negative breast cancer. Future Oncology, 2019, 15, 1951-1961.	1.1	58
74	Molecular Pathways: Targeting Hsp90â€"Who Benefits and Who Does Not. Clinical Cancer Research, 2012, 18, 4508-4513.	3.2	56
75	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational New Drugs, 2018, 36, 848-859.	1.2	55
76	A phase 2 trial of neoadjuvant metformin in combination with trastuzumab and chemotherapy in women with early HER2-positive breast cancer: the METTEN study. Oncotarget, 2018, 9, 35687-35704.	0.8	55
77	Paclitaxel With Inhibitor of Apoptosis Antagonist, LCL161, for Localized Triple-Negative Breast Cancer, Prospectively Stratified by Gene Signature in a Biomarker-Driven Neoadjuvant Trial. Journal of Clinical Oncology, 2018, 36, 3126-3133.	0.8	52
78	Multiple modes of action of eribulin mesylate: Emerging data and clinical implications. Cancer Treatment Reviews, 2018, 70, 190-198.	3.4	52
79	Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2. European Journal of Cancer, 2018, 103, 147-154.	1.3	52
80	Extracellular HMGA1 Promotes Tumor Invasion and Metastasis in Triple-Negative Breast Cancer. Clinical Cancer Research, 2018, 24, 6367-6382.	3.2	52
81	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. Lancet Oncology, The, 2020, 21, 1455-1464.	5.1	52
82	Targeting brain metastases in breast cancer. Cancer Treatment Reviews, 2022, 103, 102324.	3.4	46
83	Beyond taxanes: the next generation of microtubule-targeting agents. Breast Cancer Research and Treatment, 2012, 133, 821-830.	1.1	44
84	A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: An analysis of the ATHENA trial. Breast, 2014, 23, 656-662.	0.9	42
85	Advances in the management of HER2-positive early breast cancer. Critical Reviews in Oncology/Hematology, 2017, 119, 113-122.	2.0	42
86	Drug Interaction Potential of Trastuzumab Emtansine (T-DM1) Combined with Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer. Current Drug Metabolism, 2012, 13, 911-922.	0.7	41
87	High absolute lymphocyte counts are associated with longer overall survival in patients with metastatic breast cancer treated with eribulinâ€"but not with treatment of physicianâ€™s choiceâ€"in the EMBRACE study. Breast Cancer, 2020, 27, 706-715.	1.3	41
88	Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer. Cancer Treatment Reviews, 2012, 38, 143-151.	3.4	40
89	Prolonged survival in patients with breast cancer and a history of brain metastases: results of a preplanned subgroup analysis from the randomized phase III BEACON trial. Breast Cancer Research and Treatment, 2017, 165, 329-341.	1.1	40
90	Lucitanib for the Treatment of HR+/HER2â^' Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study. Clinical Cancer Research, 2020, 26, 354-363.	3.2	40

#	Article	IF	Citations
91	Gene expressionâ€based classifications of fibroadenomas and phyllodes tumours of the breast. Molecular Oncology, 2015, 9, 1081-1090.	2.1	39
92	The next era of treatment for hormone receptor-positive, HER2-negative advanced breast cancer: Triplet combination-based endocrine therapies. Cancer Treatment Reviews, 2017, 61, 53-60.	3.4	39
93	Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2â€“positive breast cancer. European Journal of Cancer, 2019, 120, 1-9.	1.3	39
94	Dasatinib plus Capecitabine for Advanced Breast Cancer: Safety and Efficacy in Phase I Study CA180004. Clinical Cancer Research, 2013, 19, 1884-1893.	3.2	38
95	Translating neoadjuvant therapy into survival benefits: one size does not fit all. Nature Reviews Clinical Oncology, 2016, 13, 566-579.	12.5	38
96	Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges. BioDrugs, 2020, 34, 611-623.	2.2	38
97	Intensive Loading Dose of Trastuzumab Achieves Higher-Than-Steadyâ€“State Serum Concentrations and Is Well Tolerated. Journal of Clinical Oncology, 2010, 28, 960-966.	0.8	37
98	Establishing the origin of metastatic deposits in the setting of multiple primary malignancies: The role of massively parallel sequencing. Molecular Oncology, 2014, 8, 150-158.	2.1	37
99	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	3.0	36
100	Subgroup Analyses from a Phase 3, Open-Label, Randomized Study of Eribulin Mesylate versus Capecitabine in Pretreated Patients with Advanced or Metastatic Breast Cancer. Breast Cancer: Basic and Clinical Research, 2016, 10, BCBCR.S39615.	0.6	36
101	Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases. Oncotarget, 2018, 9, 20617-20630.	0.8	36
102	Methylthioadenosine (MTA) inhibits melanoma cell proliferation and in vivotumor growth. BMC Cancer, 2010, 10, 265.	1.1	35
103	Contribution of ADAMTS1 as a tumor suppressor gene in human breast carcinoma. Linking its tumor inhibitory properties to its proteolytic activity on nidogenâ€1 and nidogenâ€2. International Journal of Cancer, 2013, 133, 2315-2324.	2.3	34
104	Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. Breast, 2017, 33, 8-13.	0.9	34
105	PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER) [+]/HER2 [-] metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, 1007-1007.	0.8	34
106	Evaluation of Pathologic Complete Response as a Surrogate for Long-Term Survival Outcomes in Triple-Negative Breast Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 1096-1104.	2.3	33
107	18F-fluoromisonidazole PET and Activity of Neoadjuvant Nintedanib in Early HER2-Negative Breast Cancer: A Window-of-Opportunity Randomized Trial. Clinical Cancer Research, 2017, 23, 1432-1441.	3.2	32
108	Immune checkpoint inhibitors: a physiology-driven approach to the treatment of coronavirus disease 2019. European Journal of Cancer, 2020, 135, 62-65.	1.3	32

#	Article	IF	Citations
109	Advances in First-Line Treatment for Patients with HER-2+ Metastatic Breast Cancer. Oncologist, 2012, 17, 631-644.	1.9	31
110	Molecular Features of Metaplastic Breast Carcinoma: An Infrequent Subtype of Triple Negative Breast Carcinoma. Cancers, 2020, 12, 1832.	1.7	30
111	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant therapy followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2018, 36, TPS602-TPS602.	0.8	30
112	Different Prognostic Implications of Residual Disease After Neoadjuvant Treatment: Impact of Ki 67 and Site of Response. Annals of Surgical Oncology, 2016, 23, 3831-3837.	0.7	29
113	HER2 and hormone receptor-positive breast cancerâ€"blocking the right target. Nature Reviews Clinical Oncology, 2011, 8, 307-311.	12.5	28
114	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 2015, 16, 575.	0.7	28
115	Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosis. Breast, 2013, 22, 19-23.	0.9	27
116	Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer. Cancer Treatment Reviews, 2018, 63, 144-155.	3.4	26
117	Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (â€œMETRICâ€): a randomized multicenter study. Npj Breast Cancer, 2021, 7, 57.	2.3	26
118	A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer. Breast Cancer Research and Treatment, 2017, 165, 601-609.	1.1	25
119	Sacituzumab govitecan as second-line treatment for metastatic triple-negative breast cancerâ€"phase 3 ASCENT study subanalysis. Npj Breast Cancer, 2022, 8, .	2.3	25
120	The use of bevacizumab among women with metastatic breast cancer: A survey on clinical practice and the ongoing controversy. Cancer, 2012, 118, 2780-2786.	2.0	24
121	Outcome of patients following hepatic resection for metastatic cutaneous and ocular melanoma. Journal of Hepato-Biliary-Pancreatic Sciences, 2011, 18, 268-275.	1.4	23
122	Safety of bevacizumab in metastatic breast cancer patients undergoing surgery. European Journal of Cancer, 2012, 48, 475-481.	1.3	23
123	nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer. Clinical Breast Cancer, 2021, 21, 181-190.e2.	1.1	23
124	Small-Cell Cancer of the Breast: What Is the Optimal Treatment? A Report and Review of Outcomes. Clinical Breast Cancer, 2012, 12, 287-292.	1.1	22
125	Multidisciplinary approach to breast cancer diagnosed during pregnancy: Maternal and neonatal outcomes. Breast, 2013, 22, 515-519.	0.9	22
126	New approach to cancer therapy based on a molecularly defined cancer classification. Ca-A Cancer Journal for Clinicians, 2014, 64, 70-74.	157.7	22

#	Article	IF	Citations
127	Randomized Phase 0/I Trial of the Mitochondrial Inhibitor ME-344 or Placebo Added to Bevacizumab in Early HER2-Negative Breast Cancer. Clinical Cancer Research, 2020, 26, 35-45.	3.2	22
128	Pembrolizumab plus eribulin in hormone-receptorâ€“positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase â...¡ trial. European Journal of Cancer, 2021, 148, 382-394.	1.3	22
129	Chemotherapy (CT) de-escalation using an FDG-PET/CT (F-PET) and pathological response-adapted strategy in HER2[+] early breast cancer (EBC): PHERGain Trial.. Journal of Clinical Oncology, 2020, 38, 503-503.	0.8	22
130	Combined Irinotecan, Oxaliplatin and 5-Fluorouracil in Patients with Advanced Colorectal Cancer. Oncology, 2002, 63, 254-265.	0.9	21
131	How to Treat Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Amplified Breast Cancer. Journal of Clinical Oncology, 2009, 27, 5492-5494.	0.8	21
132	Pregnancy after treatment of breast cancer in young women does not adversely affect the prognosis. Breast, 2012, 21, 272-275.	0.9	21
133	Use of Pertuzumab for the Treatment of HER2-Positive Metastatic Breast Cancer. Advances in Therapy, 2013, 30, 645-658.	1.3	21
134	Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial. Breast Cancer Research, 2020, 22, 124.	2.2	21
135	Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?. Breast, 2012, 21, 604-607.	0.9	20
136	Atezolizumab in the treatment of metastatic triple-negative breast cancer. Expert Opinion on Biological Therapy, 2020, 20, 981-989.	1.4	20
137	Progress Against Solid Tumors in Danger: The Metastatic Breast Cancer Example. Journal of Clinical Oncology, 2012, 30, 3444-3447.	0.8	18
138	Change in Topoisomerase 1â€“Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol. Clinical Cancer Research, 2018, 24, 3348-3357.	3.2	18
139	POSEIDON Trial Phase 1b Results: Safety, Efficacy and Circulating Tumor DNA Response of the Beta Isoform-Sparing PI3K Inhibitor Taselisib (GDC-0032) Combined with Tamoxifen in Hormone Receptor Positive Metastatic Breast Cancer Patients. Clinical Cancer Research, 2019, 25, 6598-6605.	3.2	17
140	The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin. Frontiers in Oncology, 2019, 9, 193.	1.3	17
141	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. Breast Cancer Research and Treatment, 2017, 163, 535-544.	1.1	16
142	Third-line treatment of HER2-positive advanced breast cancer: From no standard to a Pandora's box. Biochimica Et Biophysica Acta: Reviews on Cancer, 2021, 1875, 188487.	3.3	16
143	Trastuzumab deruxtecan in HER2-positive metastatic breast cancer and beyond. Expert Opinion on Biological Therapy, 2021, 21, 811-824.	1.4	16
144	AMEERA-5: a randomized, double-blind phase 3 study of amcenestrant plus palbociclibversusletrozole plus palbociclib for previously untreated ER+/HER2â€“ advanced breast cancer. Therapeutic Advances in Medical Oncology, 2022, 14, 175883592210839.	1.4	16

#	Article	IF	Citations
145	Cost-effectiveness analyses of docetaxel versus paclitaxel once weekly in patients with metastatic breast cancer in progression following anthracycline chemotherapy, in Spain. Clinical and Translational Oncology, 2010, 12, 692-700.	1.2	15
146	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. Cancer and Metastasis Reviews, 2016, 35, 323-332.	2.7	15
147	CDK4/6 Inhibitors in Hormone Receptor-Positive Metastatic Breast Cancer: Current Practice and Knowledge. Cancers, 2020, 12, 2480.	1.7	15
148	Evaluation of the TCR Repertoire as a Predictive and Prognostic Biomarker in Cancer: Diversity or Clonality?. Cancers, 2022, 14, 1771.	1.7	15
149	Docetaxel combined with targeted therapies in metastatic breast cancer. Cancer Treatment Reviews, 2012, 38, 387-396.	3.4	14
150	Health-related quality of life in patients with locally recurrent or metastatic breast cancer treated with etirinotecan pegol versus treatment of physician's choice: Results from the randomised phase III BEACON trial. European Journal of Cancer, 2017, 76, 205-215.	1.3	14
151	Preoperative chemoradiation with oral tegafur within a multidisciplinary therapeutic approach in patients with T3-4 rectal cancer. International Journal of Radiation Oncology Biology Physics, 2005, 61, 1378-1384.	0.4	13
152	The Global Landscape of Treatment Standards for Breast Cancer. Journal of the National Cancer Institute, 2021, 113, 1143-1155.	3.0	13
153	Epithelial Mesenchymal Transition and Immune Response in Metaplastic Breast Carcinoma. International Journal of Molecular Sciences, 2021, 22, 7398.	1.8	13
154	Phase II, Multicenter, Single-arm Trial of Eribulin as First-line Therapy for Patients With Aggressive Taxane-pretreated HER2-Negative Metastatic Breast Cancer: The MERIBEL Study. Clinical Breast Cancer, 2019, 19, 105-112.	1.1	12
155	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. British Journal of Cancer, 2021, 124, 1581-1591.	2.9	12
156	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers, 2021, 13, 4421.	1.7	12
157	Lkb1 Loss Promotes Tumor Progression of BRAFV600E-Induced Lung Adenomas. PLoS ONE, 2013, 8, e66933.	1.1	11
158	Phase Ib Dose-escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women with HR+, HER2â˜ Advanced Breast Cancer. Clinical Cancer Research, 2020, 26, 6417-6428.	3.2	11
159	Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer. OncoTargets and Therapy, 2011, 4, 185.	1.0	10
160	Immune analysis of lymph nodes in relation to the presence or absence of tumor infiltrating lymphocytes in triple-negative breast cancer. European Journal of Cancer, 2021, 148, 134-145.	1.3	10
161	Overall survival (OS) in patients (Pts) with diagnostic positive (Dx+) breast cancer: Subgroup analysis from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in AR+ triple-negative breast cancer (TNBC) treated with 0-1 prior lines of therapy.. Journal of Clinical Oncology, 2017, 35, 1089-1089.	0.8	10
162	KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptorâ€“positive, human epidermal growth factor receptor 2â€“negative (ER+/HER2â˜) breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS601-TPS601.	0.8	10

#	Article	IF	Citations
163	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. Therapeutic Advances in Medical Oncology, 2021, 13, 175883592110595.	1.4	10
164	Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST Analysis. Clinical Breast Cancer, 2018, 18, e919-e926.	1.1	9
165	Independent Validation of the PAM50-Based Chemo-Endocrine Score (CES) in Hormone Receptorâ€“Positive HER2-Positive Breast Cancer Treated with Neoadjuvant Antiâ€“HER2-Based Therapy. Clinical Cancer Research, 2021, 27, 3116-3125.	3.2	9
166	Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.. Journal of Clinical Oncology, 2012, 30, 598-598.	0.8	9
167	Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial. Npj Breast Cancer, 2021, 7, 145.	2.3	9
168	Gene signatures in patients with early breast cancer and relapse despite pathologic complete response. Npj Breast Cancer, 2022, 8, 42.	2.3	9
169	Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03.. Journal of Clinical Oncology, 2022, 40, 1000-1000.	0.8	9
170	The AURORA pilot study for molecular screening of patients with advanced breast cancerâ€“a study of the breast international group. Npj Breast Cancer, 2017, 3, 23.	2.3	8
171	A phase III, open-label, randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes: Subgroup analyses.. Journal of Clinical Oncology, 2013, 31, 1049-1049.	0.8	8
172	Risk of Venous Thromboembolism With Bevacizumab in Cancer Patients. JAMA - Journal of the American Medical Association, 2009, 301, 1434.	3.8	7
173	Prognostic and predictive factors and genetic analysis of early breast cancer. Clinical and Translational Oncology, 2009, 11, 634-642.	1.2	7
174	Bone metastases: Causes, consequences and therapeutic opportunities. European Journal of Cancer, Supplement, 2013, 11, 254-256.	2.2	7
175	Impact of the number of prior chemotherapy regimens on outcomes for patients with metastatic breast cancer treated with eribulin: A post hoc pooled analysis. Breast Journal, 2020, 26, 1347-1351.	0.4	7
176	Trastuzumab Emtansine Plus Non-Pegylated Liposomal Doxorubicin in HER2-Positive Metastatic Breast Cancer (Thelma): A Single-Arm, Multicenter, Phase Ib Trial. Cancers, 2020, 12, 3509.	1.7	7
177	Adverse events with pertuzumab and trastuzumab: Evolution during treatment with and without docetaxel in CLEOPATRA.. Journal of Clinical Oncology, 2012, 30, 597-597.	0.8	7
178	Clinical, Pathological, and Molecular Features of Breast Carcinoma Cutaneous Metastasis. Cancers, 2021, 13, 5416.	1.7	7
179	Anthracyclines for Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer: Are We Ready to Let Them Go?. Journal of Clinical Oncology, 2021, 39, 3541-3545.	0.8	6
180	A randomized phase III study of vinflunine versus an alkylating agent of physicianâ€™s choice in metastatic breast cancer (MBC) previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid.. Journal of Clinical Oncology, 2015, 33, 1031-1031.	0.8	6

#	Article	IF	Citations
181	KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo (PBO) + chemo for previously untreated, locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2018, 36, TPS18-TPS18.	0.8	6
182	Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials.. Journal of Clinical Oncology, 2019, 37, 571-571.	0.8	6
183	Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 82-92.	1.8	6
184	Eribulin mesylate: a promising new antineoplastic agent for locally advanced or metastatic breast cancer. Future Oncology, 2011, 7, 355-364.	1.1	5
185	Do we need biomarkers to predict the benefit of adding adjuvant taxanes for treatment of breast cancer?. Breast Cancer Research, 2012, 14, 104.	2.2	5
186	Safety and tolerability of etirinotecan pegol in advanced breast cancer: analysis of the randomized, phase 3 BEACON trial. SpringerPlus, 2016, 5, 1033.	1.2	5
187	Hydrodynamic and Electrophoretic Properties of Trastuzumab/HER2 Extracellular Domain Complexes as Revealed by Experimental Techniques and Computational Simulations. International Journal of Molecular Sciences, 2019, 20, 1076.	1.8	5
188	SOLTI-1303 PATRICIA: A phase II study of palbociclib and trastuzumab (HR+ with or without letrozole) in trastuzumabâ€pretreated, postmenopausal patients with HER2â€positive metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, TPS1101-TPS1101.	0.8	5
189	Differences in the Molecular Profile between Primary Breast Carcinomas and Their Cutaneous Metastases. Cancers, 2022, 14, 1151.	1.7	5
190	Paclitaxel, Cisplatin, and Vinorelbine Combination Chemotherapy in Metastatic Nonâ€“Small-Cell Lung Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2004, 27, 299-303.	0.6	4
191	CXCR4 antagonists for treatment of breast cancer. Oncotarget, 2018, 9, 33442-33443.	0.8	4
192	Quality of life (QoL) in patients (pts) with locally advanced or metastatic breast cancer (MBC) previously treated with anthracyclines and taxanes who received eribulin mesylate or capecitabine: A phase III, open-label, randomized study.. Journal of Clinical Oncology, 2013, 31, 1050-1050.	0.8	4
193	Phase III trial of non-pegylated liposomal doxorubicin (M) in combination with trastuzumab (T) and paclitaxel (P) in HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, 517-517.	0.8	4
194	A prognostic factor (PF) index for overall survival in a HER2-negative endocrine-resistant metastatic breast cancer (MBC) population: Analysis from the ATHENA trial.. Journal of Clinical Oncology, 2013, 31, 555-555.	0.8	4
195	Phase 1b/2 trial of BI 836845, an insulin-like growth factor (IGF) ligand-neutralizing antibody, combined with exemestane (Ex) and everolimus (Ev) in hormone receptor-positive (HR+) locally advanced or metastatic breast cancer (BC): primary phase 1b results.. Journal of Clinical Oncology, 2016, 34, 530-530.	0.8	4
196	Pembrolizumab Plus Gemcitabine in the Subset of Triple-Negative Advanced Breast Cancer Patients in the GEICAM/2015-04 (PANGEA-Breast) Study. Cancers, 2021, 13, 5432.	1.7	4
197	CDK4/6 inhibitors in breast cancer: spotting the difference. Nature Medicine, 2021, 27, 1868-1869.	15.2	4
198	Spurring science, marking progress, and influencing history. Nature Reviews Clinical Oncology, 2018, 15, 79-80.	12.5	3

#	Article	IF	Citations
199	Contextualizing pertuzumab approval in the treatment of HER2-positive breast cancer patients. Cancer Treatment Reviews, 2020, 83, 101944.	3.4	3
200	PI3K pathway (PI3Kp) dysregulation and response to pan-PI3K/AKT/mTOR/dual PI3K-mTOR inhibitors (PI3Kpi) in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 509-509.	0.8	3
201	Phase III trial of etirinotecan pegol (EP) versus Treatment of Physicianâ€™s Choice (TPC) in patients (pts) with advanced breast cancer (aBC) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study.. Journal of Clinical Oncology, 2015, 33, 1001-1001.	0.8	3
202	HERMIONE: A Phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physicianâ€™s choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and ado-trastuzumab emtansine (T-DM1).. Journal of Clinical Oncology, 2015, 33, TPS641-TPS641.	0.8	3
203	XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement.. Journal of Clinical Oncology, 2019, 37, TPS1103-TPS1103.	0.8	3
204	Clonality of PIK3CA mutations (mut) and efficacy of PI3K/AKT/mTOR inhibitors (PAMi) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2016, 34, 528-528.	0.8	3
205	nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HRâ€‰+â€‰, HER2â€“ metastatic breast cancer. Breast Cancer Research and Treatment, 2022, 195, 55-64.	1.1	3
206	Circulating tumour cells in early breast cancer. Lancet Oncology, The, 2012, 13, e370.	5.1	2
207	Potential clinical applications of halichondrins in breast cancer and other neoplasms. Breast Cancer: Targets and Therapy, 2012, 4, 9.	1.0	2
208	Adjuvant bevacizumab: positive data from a negative trial. Lancet Oncology, The, 2013, 14, 910-911.	5.1	2
209	The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer. Current Breast Cancer Reports, 2014, 6, 51-58.	0.5	2
210	Influencing cancer treatment. Lancet Oncology, The, 2015, 16, 1591-1593.	5.1	2
211	Etirinotecan pegol for the treatment of breast cancer. Expert Opinion on Pharmacotherapy, 2016, 17, 727-734.	0.9	2
212	The new world of biosimilars in oncology: Translation ofÂdataÂto the clinic. European Journal of Cancer, 2018, 96, 125-127.	1.3	2
213	Immunotherapy for HER2-Positive Breast Cancer: Changing the Paradigm. Current Breast Cancer Reports, 2019, 11, 248-258.	0.5	2
214	The temporal mutational and immune tumour microenvironment remodelling of HER2-negative primary breast cancers. Npj Breast Cancer, 2021, 7, 73.	2.3	2
215	Phase I dose-escalation, open-label study of HSP990 administered orally in adult patients with advanced solid malignancies.. Journal of Clinical Oncology, 2013, 31, 2561-2561.	0.8	2
216	Trastuzumab emtansine (T-DM1) plus capecitabine (X) in patients with HER2-positive MBC: MO28230 TRAX-HER2 phase 1 results.. Journal of Clinical Oncology, 2014, 32, 606-606.	0.8	2

#	Article	IF	Citations
217	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.. Journal of Clinical Oncology, 2014, 32, 631-631.	0.8	2
218	FINESSE: An open, three-cohort, phase II trial testing oral administration of lucitanib in patients with FGFR1-amplified or nonamplified estrogen receptor-positive metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS1134-TPS1134.	0.8	2
219	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2014, 32, TPS1146-TPS1146.	0.8	2
220	Survival in triple-negative breast cancer (TNBC): Evidence from the SEER database 2010-2011.. Journal of Clinical Oncology, 2015, 33, e12075-e12075.	0.8	2
221	Prognostic and therapeutic implications of fibroblast growth factor receptors (FGFRs) 1 and 2 gene amplifications in patients (pts) with advanced breast cancer (ABC).. Journal of Clinical Oncology, 2016, 34, 537-537.	0.8	2
222	Epsteinâ€“Barr Virus+ B Cells in Breast Cancer Immune Response: A Case Report. Frontiers in Immunology, 2021, 12, 761798.	2.2	2
223	A roadmap for accelerated drug approval in breast cancer?. Lancet Oncology, The, 2012, 13, 850-851.	5.1	1
224	Evolution of Angiogenic Factors in Pregnant Patients with Breast Cancer Treated with Chemotherapy. Cancers, 2021, 13, 923.	1.7	1
225	Pembrolizumab plus chemotherapy in triple-negative breast cancer â€“ Authors' reply. Lancet, The, 2021, 398, 24-25.	6.3	1
226	A phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. Journal of Clinical Oncology, 2012, 30, TPS652-TPS652.	0.8	1
227	Is the proportion of patients with synchronous stage IV breast cancer surviving > 2 years increasing over time?. Journal of Clinical Oncology, 2013, 31, 524-524.	0.8	1
228	The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2013, 31, TPS1136-TPS1136.	0.8	1
229	Correlation of high levels of HER2 measured by multiplex mass spectrometry with increased overall survival in patients treated with anti-HER2-based therapy.. Journal of Clinical Oncology, 2014, 32, 649-649.	0.8	1
230	HER2 quantification by mass spectrometry compared to IHC or ISH in predicting clinical benefit from anti-HER2 therapy in HER2-positive breast cancer (BC).. Journal of Clinical Oncology, 2015, 33, 605-605.	0.8	1
231	Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, TPS1106-TPS1106.	0.8	1
232	Final results of a phase II trial of trabectedin (T) in patients with hormone receptor-positive, HER2-negative advanced breast cancer, according to xeroderma pigmentosum gene (XPG) expression.. Journal of Clinical Oncology, 2013, 31, 547-547.	0.8	1
233	Targeting HSP90 in breast cancer: Enchant-1 (NCT01677455) phase 2 proof of concept study of ganetespib in first-line treatment of women with metastatic breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS665-TPS665.	0.8	1
234	Impact of marital status on prognostic outcome of women with breast cancer.. Journal of Clinical Oncology, 2014, 32, 594-594.	0.8	1

#	Article	IF	Citations
235	ARB: Phase II window of opportunity study of short-term preoperative treatment with enzalutamide in ER-positive and triple-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, TPS619-TPS619.	0.8	1
236	Acknowledgements. Expert Review of Anticancer Therapy, 2012, 12, 1369-1369.	1.1	0
237	Bevacizumab in advanced breast cancer. Anti-Cancer Drugs, 2013, 24, 975-979.	0.7	0
238	Reply to A. Ocana et al. Journal of Clinical Oncology, 2013, 31, 1253-1254.	0.8	0
239	Reply to K.S. Shohdy et al. Journal of Clinical Oncology, 2018, 36, 2458-2459.	0.8	0
240	Nobody dares stopping clinical research, not even COVID-19. Npj Breast Cancer, 2021, 7, 39.	2.3	0
241	I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment. Cancer Cell, 2021, 39, 902-904.	7.7	0
242	Presentation and treatment of HER2-positive metastatic breast cancer patients already treated with adjuvant trastuzumab.. Journal of Clinical Oncology, 2012, 30, 619-619.	0.8	0
243	Prognostic significance of PI3K pathway (PI3Kp) dysregulation in metastatic breast cancer (MBC) patients (pts).. Journal of Clinical Oncology, 2012, 30, 566-566.	0.8	0
244	Analysis of the intratumoral heterogeneity of PIK3CA mutant alleles in breast cancer (BC): Implications for the luminal (LUM) phenotype.. Journal of Clinical Oncology, 2012, 30, 10511-10511.	0.8	0
245	Phase III open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients (pts) with locally recurrent or metastatic breast cancer (MBC) previously treated with an anthracycline, a taxane, and capecitabine (ATC).. Journal of Clinical Oncology, 2012, 30, TPS1140-TPS1140.	0.8	0
246	Impact of surgery and radiation of the primary among women with de novo stage IV breast cancer.. Journal of Clinical Oncology, 2012, 30, 1032-1032.	0.8	0
247	HER2-Positive Metastatic Breast Cancer: First-Line Treatment. , 2013, , 43-60.		0
248	PAM50 HER2-enriched (HER2E) phenotype as a predictor of early-response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.. Journal of Clinical Oncology, 2013, 31, TPS665-TPS665.	0.8	0
249	Early prediction of efficacy of endocrine therapy in breast cancer (BC): Pilot study and validation with 18F fluoroestradiol (18F-FES) PET/CT.. Journal of Clinical Oncology, 2013, 31, TPS649-TPS649.	0.8	0
250	Quality of life (QoL) and content validity in objective tumor response.. Journal of Clinical Oncology, 2013, 31, 1055-1055.	0.8	0
251	Incidence and characteristics of breast cancer following a diagnosis of ductal carcinoma in situ.. Journal of Clinical Oncology, 2013, 31, 1131-1131.	0.8	0
252	A phase II randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2-normal advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, TPS653-TPS653.	0.8	0

#	Article	IF	Citations
253	Incorporation of FGFR1 and FGFR2 amplification status determination in routine molecular prescreening for targeted therapies.. Journal of Clinical Oncology, 2014, 32, 11105-11105.	0.8	0
254	Effect of age and tumor size on prognostic outcome of women with breast cancer.. Journal of Clinical Oncology, 2014, 32, 592-592.	0.8	0
255	Efficacy of eribulin in patients (pts) with metastatic breast cancer (MBC): A pooled analysis by HER2 and ER status.. Journal of Clinical Oncology, 2014, 32, 137-137.	0.8	0
256	Impact of locoregional therapy among women 70 years or older with early stage hormone receptor positive breast cancer: A population based study.. Journal of Clinical Oncology, 2015, 33, 573-573.	0.8	0
257	Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).. Journal of Clinical Oncology, 2015, 33, TPS1106-TPS1106.	0.8	0
258	HER2-positive metastatic breast cancer: first-line treatment. , 2016, , 51-69.		0